Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines

被引:107
|
作者
Bauer, Michael [1 ]
Severus, Emanuel [1 ]
Moller, Hans-Jurgen [2 ]
Young, Allan H. [3 ]
机构
[1] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Psychiat & Psychotherapy, Fetscherstr 74, D-01307 Dresden, Germany
[2] Ludwig Maximilians Univ Munchen, Dept Psychiat, Munich, Germany
[3] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol Med, London, England
关键词
Primary care; major depressive disorder; pharmacotherapy; guidelines; CONTINUATION TREATMENT; BIOLOGICAL TREATMENT; CONTROLLED-TRIALS; MAJOR DEPRESSION; WORLD FEDERATION; DOUBLE-BLIND; ANTIDEPRESSANTS; METAANALYSIS; UPDATE; MANAGEMENT;
D O I
10.1080/13651501.2017.1306082
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Major depressive disorder (MDD) is a severe mood disorder affecting individuals of all ages and is characterised by single or recurrent major depressive episodes. Key elements of acute and maintenance treatment of MDD include pharmacotherapy, and psychological approaches such as psychoeducation and adherence monitoring.Methods: This summary of the Practice guidelines for the biological treatment of unipolar depressive disorders' comprises acute, continuation and maintenance treatment developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP), and focuses on pharmacological treatment options.Results: A variety of different antidepressants are available for the effective acute and prophylactic treatment of depressed patients. Randomised placebo-controlled efficacy studies indicate that all major classes of antidepressants are effective in acute treatment but also in preventing recurrence of depression showing about a two-fold higher relapse rate with placebo treatment. Evidence suggests that the newer' antidepressants have superior long-term effectiveness due to better tolerability and safety profile compared to traditional antidepressants, e.g., the tricyclic antidepressants (TCA).Conclusions: Despite progress in the availability of different treatment options there is still a substantial proportion of patients who do not achieve full remission. Several add-on pharmacological treatment options are among the best-evidenced strategies for refractory depressed patients.
引用
收藏
页码:166 / 176
页数:11
相关论文
共 50 条
  • [21] Commentary on guidelines for the pharmacological treatment of paraphilic disorders
    Krueger, Richard B.
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2020, 21 (06): : 409 - 411
  • [22] Depressive episodes in bipolar and unipolar disorders
    Forty, Liz
    Jones, Lisa
    Jones, Ian
    Craddock, Nick
    BIPOLAR DISORDERS, 2006, 8 : 47 - 47
  • [23] Anger attacks in unipolar depressive disorders
    Fava, M
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 1997, 23 : 39 - 42
  • [24] The effect of Axis II disorders on the outcome of treatment of anxiety and unipolar depressive disorders: A review
    Reich, J
    JOURNAL OF PERSONALITY DISORDERS, 2003, 17 (05) : 387 - 405
  • [25] Diagnosis and pharmacological treatment of depressive disorders in a general hospital
    Cigognini, Marco Aurlio
    Furlanetto, Leticia Maria
    REVISTA BRASILEIRA DE PSIQUIATRIA, 2006, 28 (02) : 97 - 103
  • [26] The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the treatment of adolescent sexual offenders with paraphilic disorders
    Thibaut, Florence
    Bradford, John M. W.
    Briken, Peer
    De la Barra, Flora
    Haessler, Frank
    Cosyns, Paul
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2016, 17 (01): : 2 - 38
  • [27] Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
    Taylor, Rachael W.
    Marwood, Lindsey
    Oprea, Emanuella
    DeAngel, Valeria
    Mather, Sarah
    Valentini, Beatrice
    Zahn, Roland
    Young, Allan H.
    Cleare, Anthony J.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2020, 23 (09): : 587 - 625
  • [28] World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders - First Revision
    Bandelow, Borwin
    Zohar, Joseph
    Hollander, Eric
    Kasper, Siegfried
    Moeller, Hans-Juergen
    Allgulander, Christer
    Ayuso-Gutierrez, Jose
    Baldwin, David
    Bunevicius, Robertas
    Cassano, Giovanni
    Fineberg, Naomi
    Gabriels, Loes
    Hindmarch, Ian
    Kaiya, Hisanobu
    Klein, Donald F.
    Lader, Malcolm
    Lecrubier, Yves
    Lepine, Jean-Pierre
    Liebowitz, Michael R.
    Lopez-Ibor, Juan Jose
    Marazziti, Donatella
    Miguel, Euripedes C.
    Oh, Kang Seob
    Preter, Maurice
    Rupprecht, Rainer
    Sato, Mitsumoto
    Starcevic, Vladan
    Stein, Dan J.
    van Ameringen, Michael
    Vega, Johann
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2008, 9 (04): : 248 - 312
  • [29] The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, Part II:: Treatment of mania
    Grunze, H
    Kasper, S
    Goodwin, G
    Bowden, C
    Baldwin, D
    Licht, RW
    Vieta, E
    Möller, HJ
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2003, 4 (01): : 5 - 13
  • [30] The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III:: Maintenance treatment
    Grunze, H
    Kasper, S
    Goodwin, G
    Bowden, C
    Möller, HJ
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2004, 5 (03): : 120 - 135